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Background:	 Rhinovirus	 (RV)	 causes	 the	 common	cold	 and	 asthma	exacerbations.	
The	RV	genome	is	a	7.3	kb	single-	strand	positive-	sense	RNA.
Objective:	Using	minor	group	RV1A	as	a	backbone,	we	sought	to	design	and	generate	
a	recombinant	RV1A	accommodating	fluorescent	marker	expression,	thereby	allow-
ing	tracking	of	viral	infection.
Method:	Recombinant	RV1A	infectious	cDNA	clones	harboring	the	coding	sequence	
of	 green	 fluorescent	protein	 (GFP),	Renilla	 luciferase,	or	 iLOV	 (for	 light,	 oxygen,	or	
voltage	sensing)	were	engineered	and	constructed.	RV-	infected	cells	were	determined	
by	flow	cytometry,	immunohistochemistry,	and	immunofluorescence	microscopy.
Results:	RV1A-	GFP	showed	a	cytopathic	effect	 in	HeLa	cells	but	failed	to	express	
GFP	or	Renilla	luciferase	due	to	deletion.	The	smaller	fluorescent	protein	construct,	
RV1A-	iLOV,	was	stably	expressed	in	infected	cells.	RV1A-	iLOV	expression	was	used	
to	examine	the	antiviral	effect	of	bafilomycin	 in	HeLa	cells.	Compared	to	parental	
virus,	RV1A-	iLOV	infection	of	BALB/c	mice	yielded	a	similar	viral	 load	and	level	of	
cytokine	mRNA	expression.	However,	imaging	of	fixed	lung	tissue	failed	to	reveal	a	
fluorescent	 signal,	 likely	 due	 to	 the	 oxidation	 and	 bleaching	 of	 iLOV-	bound	 flavin	
mononucleotide.	We	 therefore	employed	an	anti-	iLOV	antibody	 for	 immunohisto-
chemical	and	immunofluorescence	imaging.	The	iLOV	signal	was	identified	in	airway	
epithelial	cells	and	CD45+	CD11b+	lung	macrophages.
Conclusions:	 These	 results	 suggest	 that	RV1A-	iLOV	 is	 a	 useful	molecular	 tool	 for	
studying	RV	pathogenesis.	The	construction	strategy	 for	RV1A-	iLOV	could	be	ap-
plied	to	other	RV	serotypes.	However,	the	detection	of	iLOV-	expressing	RV	in	fixed	
tissue	required	the	use	of	an	anti-	iLOV	antibody,	limiting	the	value	of	this	construct.
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1  | INTRODUC TION
Rhinovirus	(RV)	is	the	most	frequent	viral	infectious	agent	of	the	re-
spiratory	tract	in	humans	and	is	the	predominant	cause	of	the	com-
mon cold.1	More	importantly,	RV	has	emerged	as	the	most	frequent	
pathogen	associated	with	asthma	exacerbations	in	infants,	children,	
and	adults.2-4
RV	 is	 placed	 in	 the	 Picornaviridae	 family,	 genus	 Enterovirus,	
with	 three	 species	 based	 on	 phylogenetic	 sequence	 criteria.5,6 
Clinical	specimens	collected	from	in	the	1960s	and	1970s	yielded	
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approximately	 100	 different	 species	A	 and	B	 strains	which	were	
subsequently	serotyped.7,8	More	recently,	a	diverse	group	of	pre-
viously	unrecognized	human	viruses	from	species	C	was	found	to	
be	common	causes	of	respiratory	illness.4	To	understand	RV	patho-
genesis,	human	and	animal	models	have	been	developed.	Human	
studies	 have	 employed	 experimental	 infection	 with	 RV-	A16.9,10 
Mouse	 studies	 have	used	RV-	A1B	wild-	type	mice11	 or	RV-	A16	 in	
mice	 that	 are	 transgenic	 for	 human	 intercellular	 adhesion	 mole-
cule-	1.12	 These	models	 have	 been	 particularly	 useful	 in	 studying	
RV-	induced	exacerbations	of	allergic	airways	disease.	To	detect	RV	
in	 the	 tissues,	 investigators	 have	 employed	 the	monoclonal	 anti-
body	R16-	7.9,13,14	This	antibody,	originally	developed	by	Wai-	Ming	
Lee	at	the	University	of	Wisconsin,	binds	to	the	VP2	capsid	protein	
of	the	closely	related	RV-	A16	and	RV-	A1	strains,6	but	not	to	RV-	A2,	
RV-	B14,	or	RV-	A49.15	Because	the	presence	of	more	than	100	dif-
ferent	RV	serotypes	makes	it	infeasible	to	develop	a	cross-	reactive	
antibody	for	RV,	we	sought	to	develop	a	recombinant	virus	with	a	
fluorescent	marker	that	could	be	used	for	tracking	of	RV	infection	
in vivo.
Similar	to	other	picornaviruses,	RV	is	icosahedral,	nonenveloped	
particle	which	is	composed	of	60	copies	each	of	four	capsid	proteins,	
VP1,	VP2,	VP3,	and	the	small	myristoylated	VP4.16,17	The	capsid	en-
cases	a	positive-	sense	single-	stranded	RNA	(ssRNA)	genome	of	ap-
proximately	7200	nucleotides.18	Following	virus	entry	and	genome	
release	into	the	host	cell	cytoplasm,	the	RV	ssRNA	is	translated	into	
a	single	polyprotein	that	undergoes	proteolytic	cleavage	by	viral	pro-
teases	2Apro	and	3Cpro,8,19,20	with	the	exception	of	the	autocatalytic	
cleavage	of	precursor	VP0	into	VP2	and	VP4	in	the	presence	of	viral	
RNA	during	the	assembly	process.21
RV	infectious	cDNA	clones	have	been	constructed	and	used	as	
a	molecular	tool	to	study	RV	viral	protein	function	and	mutation-	
phenotype	association,	as	well	as	a	vaccine	vector	for	foreign	gene	
expression.17,22-25	In	the	current	study,	we	engineered	a	recombi-
nant	RV1A	(RV1A-	iLOV)	with	insertion	of	the	coding	sequence	for	
iLOV	(for	light,	oxygen,	or	voltage	sensing),	a	small-	size	fluorescent	
marker.26	RV1A-	iLOV	is	viable,	and	 its	expressed	 iLOV	protein	 is	
trackable	both	in	vitro	and	in	vivo,	suggesting	that	RV1A-	iLOV	may	
be	 a	 useful	 tool	 in	 the	 study	 of	 RV	 pathogenesis.	 However,	 the	
detection	of	iLOV-	expressing	RV	in	fixed	tissue	required	the	use	of	
an	anti-	iLOV	antibody,	limiting	the	value	of	this	construct.
2  | MATERIAL S AND METHODS
2.1 | Cells and reagents
H1-	Hela	and	THP-	1	cells	were	purchased	from	ATCC	(Manassas,	VA).	
Plasmids	 pEGFP-	N1	 (Clontech,	 Mountain	 View,	 CA),	 pRL	 (Renilla	
luciferase;	 Promega,	 Madison,	 WI),	 and	 pUC18-	ilOV	 (GenScript,	
Piscataway,	NJ)	were	used	to	amplify	the	DNA	fragments	of	green	
fluorescent	protein	(GFP),	Renilla	 luciferase	(RL),	and	iLOV,	respec-
tively.	 (For	 the	 detailed	 iLOV	 nucleotide	 sequence,	 see	 Table	 S1.)	
Antibody	 to	 RV	 VP2/VP0	 was	 obtained	 from	 QED	 Biosciences	
(San	Diego,	CA).	Anti-	GFP	Ab	was	purchased	 from	Thermo	Fisher	
Scientific	 (Waltham,	MA).	A	synthesized	peptide	fragment	of	 iLOV	
(CLGRNARFLQGPETD)	was	 generated	 and	 used	 to	 generate	 anti-	
iLOV	antibody	(GenScript).	Bafilomycin	was	purchased	from	Merck	
Millipore	(Burlington,	MA).
2.2 | Design and construction of recombinant 
RV1A- iLOV cDNA clone
The	RV	infectious	cDNA	clone	encoding	replication-	competent	RV-	
1A,	pMJ3-	RV1A,	was	kindly	provided	by	W.	T.	Jackson,	University	of	
Maryland27	and	served	as	a	backbone	for	either	GFP-	,	RL-	,	or	iLOV-	
expressing	viruses.	GFP,	RL,	and	iLOV	open	reading	frames	(ORFs)	
were	 designed	 to	 be	 flanked	 by	 the	 edited	 nucleotide	 sequences	
encoding	 the	 viral	 2Apro	 cleavage	 site	with	 silent	mutations	 intro-
duced	 as	 described	 previously24	 (Figure	1A,	 Table	 S2).	 Respective	
GFP,	RL,	and	iLOV	inserts	were	PCR	amplified	from	existing	clones	
using	the	primers	listed	in	Table	S1.	The	PCR	products,	which	con-
tained	Apa I	restriction	enzyme	cleavage	sites	on	the	5′	and	3′	ends,	
were	digested	with	Apa I,	ligated	to	pMJ3-	RV1A,	and	transformed	in	
E. coli	 (DH5α,	Thermo	Fisher	Scientific).	The	resultant	clones	were	
sequenced	to	confirm	the	correct	orientation	of	the	inserts.
2.3 | Generation of recombinant RV
Infectious	 cDNA	 clones	 encoding	 RV1A,	 RV1A-	GFP,	 RV1A-	RL,	
and	RV1A-	iLOV	were	linearized	by	Mlu I	restriction	enzyme	diges-
tion.	To	produce	replication-	competent	virus,	full-	length	viral	RNA	
transcripts	were	generated	using	the	MEGAscript	T7	Transcription	
Kit	(Thermo	Fisher	Scientific)	and	transfected	into	H1-	HeLa	cells	
using	 Lipofectamine	 MessengerMAX	 (Thermo	 Fisher	 Scientific).	
After	 48	hours,	 cells	 underwent	 three	 freeze-	thaw	 cycles	 and	
were	subjected	to	centrifugation	at	13	800	g	for	supernatant	col-
lection.	The	virus-	containing	supernatant	stocks	were	designated	
as	passage	0	(P0).	H1-	HeLa	cells	were	subsequently	used	to	pas-
sage	 the	 virus	 for	 subsequent	 in	 vitro	 virus	 stability	 and	 in	 vivo	
studies.	RV1A-	GFP	and	RV1A-	RL	underwent	plaque	purification	
for	insert	analysis.	RV	was	concentrated	and	partially	purified	from	
infected	HeLa	cell	 lysates	by	ultrafiltration	using	a	100	kDa	cut-
off	filter,	as	described.11	Viral	quantity	was	determined	by	plaque	
assay28	 or	 quantitative	 one-	step	 real-	time	 polymerase	 chain	 re-
action	 for	 positive-	strand	 viral	 RNA	 using	 RV-	specific	 primers	
and	 probes	 (forward	 primer:	 5′-	GTGAAGAGCCSCRTGTGCT-	3′;	
reverse	 primer:	 5′-	GCTSCAGGGTTAAGGTTAGCC-	3′;	 probe:	 5′
-	FAM-	TGAGTCCTCCGGCCCCTGAATG-	TAMRA-	3′).29	 The	 limit	
of	 detection	 for	 this	 viral	 copy	 number	 analysis	 is	 between	 0	
and	 10	 copies.	 The	 presence	 of	 the	 GFP,	 RL,	 and	 iLOV	 inserts	
was	 determined	 using	 RV-	specific	 flanking	 primers	 (forward	
primer:	 5′-	CATTCTGTTGTCATCACAACACA-	3′;	 reverse	 primer:	
5′-	CACCTATAGTGTTTGTGCGGT-	3′).	 iLOV	 insert	 quantity	 was	
measured	by	quantitative	real-	time	PCR	using	specific	primers	encod-
ing	for	iLOV	(forward	primer:	5′-	GATTCCTGCAAGGACCAGAG-	3′;	
reverse	primer:	5′-	CCGCTCTTGGTGTAGTTGAT-	3′).
     |  719HAN et Al.
2.4 | iLOV immunofluorescence of cultured cells
H1-	HeLa	cells	were	infected	with	RV1A-	iLOV	at	a	multiplicity	of	infection	
(MOI)	of	0.1	for	24	h.	Infected	cells	were	then	subjected	to	fluorescent	mi-
croscopy.	In	selected	experiments,	RV1A-	iLOV–infected	cells	were	fixed	
and	stained	with	Alexa	Fluor	555–conjugated	mouse	anti-	RV	VP2/VP0	
(clone	R16-	7;	QED	Bioscience).	Images	were	visualized	using	an	Olympus	
IX71-	inverted	phase/epifluorescence	microscope	and	digital	CCD	camera.
2.5 | Animals and RV infection
Animal	 usage	 followed	 guidelines	 set	 forth	 in	 the	 Principles	 of	
Laboratory	 Animal	 Care	 from	 the	 National	 Society	 for	 Medical	
Research.	 Six-	day-	old	 or	 8-	 to	 10-	week-	old	 BALB/c	 mice	 (Jackson	
Laboratories,	 Bar	 Harbor,	ME)	were	 treated	 intranasally	with	 15	 or	
50	μL	of	108	plaque	forming	units	of	virus	and	harvested	24	hours	later.
2.6 | Histology, immunohistochemistry, and 
immunofluorescence microscop
For	histology,	mouse	 lungs	were	perfused	 through	 the	pulmonary	
artery	with	PBS	containing	5	mmol/L	EDTA	and	fixed	with	4%	para-
formaldehyde	overnight.	 For	 immunohistochemistry,	 lung	 sections	
were	stained	with	rabbit	anti-	iLOV,	then	incubated	with	biotinylated	
secondary	goat-	IgG,	ABC	reagent	(Vector	Laboratories,	Burlingame,	
CA),	 diaminobenzidine	 (DAB,	 Sigma-	Aldrich,	 St.	 Louis,	 MO,	 USA),	
and	Gill’s	hematoxylin	(Fisher	Scientific,	Kalamazoo,	MI).	For	fluores-
cence	microscopy,	slides	were	incubated	with	Alexa	Fluor	488–con-
jugated	iLOV,	Alexa	Fluor	555–conjugated	mouse	anti-	RV	VP2/VP0,	
and	Cy5–anti-	mouse	CD68	(Biolegend,	San	Diego,	CA).	Nuclei	were	
stained	with	4′,6-	diamidino-	2-	phenylindole	(DAPI).	Images	were	ac-
quired	with	a	Zeiss	ApoTome	confocal	microscope	(Microscopy	and	
Image	Analysis	Core,	University	of	Michigan).
2.7 | Quantitative real- time PCR of lung cytokines
Lung	 RNA	 was	 extracted	 with	 TRIzol	 Reagent	 (Thermo	 Fisher	
Scientific)	 combined	 with	 on-	column	 digestion	 of	 genomic	 DNA	
(QIAGEN,	Valencia,	CA).	cDNA	was	synthesized	from	1	μg	of	RNA	
and	 subjected	 to	 quantitative	 real-	time	 PCR	 using	 specific	mRNA	
primers	 encoding	 for	 IL-	1β,	 IFN-	β,	 IFN-	γ,	 CXCL1,	CXCL2,	CXCL10,	
CCL2,	CCL5,	and	IL-	10	(Table	S2).	For	each	sample,	the	level	of	gene	
expression	was	normalized	to	its	own	GAPDH	mRNA.
2.8 | Flow cytometric analysis
HeLa	cells	were	infected	with	sham,	RV1A	or	RV1A-	iLOV	at	an	MOI	
of	 0.1	 for	 24	hours.	 Cells	 were	 subjected	 to	 flow	 cytometry	 and	
analyzed	on	an	LSR	Fortessa	(BD	Biosciences,	San	Jose,	CA).	For	in	
vivo	experiments,	lungs	from	sham-	,	RV1A-	,	and	RV1A-	iLOV-	treated	
BALB/c	mice	were	perfused	with	PBS	containing	EDTA,	minced,	and	
digested	in	collagenase	IV.	Cells	were	filtered	and	washed	with	RBC	
lysis	buffer,	and	dead	cells	were	stained	with	Pac-	Orange	Live/Dead	
fixable	dead	staining	dye	(Fisher	Scientific,	Kalamazoo,	MI,	USA).	To	
identify	 iLOV-	positive	cells,	cells	were	stained	for	surface	markers	
with	anti-	CD45	(BioLegend)	and	anti-	CD11b	(Biolegend,	San	Diego,	
CA,	USA).	Cells	were	then	fixed,	permeabilized,	and	incubated	with	
the	Cy3-	tagged	anti-	iLOV	prior	 to	 flow	cytometry.	Data	were	col-
lected	and	analyzed	using	FACSDiva	 (BD	Biosciences)	 and	FlowJo	
software	(TreeStar,	Ashland,	OR).
2.9 | Data analysis
Data	 are	 represented	 as	 mean	 ±	 SE.	 Statistical	 significance	 was	
assessed	 using	 an	 unpaired	 t	 test	 or	 one-	way	 ANOVA,	 as	 appro-
priate.	 Group	 differences	 were	 pinpointed	 by	 a	 Tukey’s	 multiple-	
comparison	test.
3  | RESULTS
3.1 | Incompatibility of RV1A genome with GFP 
insert
GFP	with	flanking	2Apro	cleavage	sites	was	designed	to	be	inserted	
between	the	RV	genomic	sequences	encoding	the	VP1	and	2A	pro-
teins	(Figure	1A).	To	stabilize	the	genome,	silent	mutations	were	intro-
duced	into	the	coding	sequences	of	both	the	flanking	2Apro	cleavage	
sites	 (Table	S1),	as	described	previously.24	To	generate	viral	 stocks,	
genomic	RNA	transcripts	made	from	the	RV1A-	GFP	infectious	clone	
were	transfected	 into	H1-	HeLa	cells	followed	by	three	consecutive	
passages	 (P1-	P3).	A	 cytopathic	 effect	 (CPE)	was	observed	 in	HeLa	
cell-	infected	 RV1A-	GFP	 (Figure	1B).	 However,	 we	 were	 unable	
to	 detect	GFP	expression	by	Western	 blot	 (Figure	1C)	 or	 immuno-
fluorescence	(Figures	1D).	We	also	constructed	recombinant	RV1A-	
expressing	Renilla	 luciferase	 (RL)	protein	to	determine	whether	the	
size	of	the	GFP	insert	exceeded	the	limited	packaging	capacity	of	RV.	
To	examine	the	presence	of	intact	GFP	and	RL	ORFs	from	RV1A-	GFP	
and	RV1A-	RL,	RT-	PCR	was	performed	for	plaque-	purified	RV1A-	GFP	
and	RV1A-	RL	using	RV-	specific	flanking	primers.	Results	showed	that	
the	GFP	and	RL	sequences	were	deleted	(Figure	1E).	Sequence	analy-
sis	of	inserts	confirmed	these	results	(data	not	shown).
3.2 | Generation and characterization of RV1A- iLOV
We	 reasoned	 that	 the	 approximately	 753	nt	 GFP	 and	 1005	nt	 RL	
ORFs	 (including	engineered	flanking	sequences)	exceeded	the	 lim-
ited	packaging	capacity	of	RV.24	We	therefore	chose	an	alternative	
smaller	fluorescent	protein,	iLOV	(~366	nt).	RV1A-	iLOV	was	gener-
ated	following	the	design	and	generation	procedure	of	RV1A-	GFP.	
CPE	and	growth	kinetics	of	RV1A-	iLOV	were	determined	 in	HeLa	
cells.	In	comparison	with	the	parental	virus,	the	RV1A-	iLOV	displayed	
a	slightly	reduced	cytopathic	effect	and	growth	rate	(Figure	2A,B).	
By	 immunofluorescence,	 iLOV	 signal	 (green)	 appeared	 in	 RV1A-	
iLOV–infected	cells	only,	further	confirming	the	expression	of	iLOV	
(Figure	2C).	 Western	 blot	 analysis	 using	 rabbit	 sera	 recognizing	
the	iLOV	protein	showed	expression	of	a	product	of	the	predicted	
720  |     HAN et Al.
molecular	 weight	 in	 RV1A-	iLOV–infected	 cells	 (Figure	2D),	 while	
viral	capsid	proteins	VP0	and	VP2	were	detected	in	both	RV1A-	and	
RV1A-	iLOV–infected	cells.
3.3 | Genetic stability of RV1A- iLOV in cell culture
Next,	we	examined	the	genetic	stability	of	RV1A-	iLOV	in	HeLa	cells.	
iLOV	expression	was	observed	 in	RV1A-	iLOV	P1-	and	P5-	infected	
HeLa	cells	by	live-	cell	imaging	and	flow	cytometry	(Figure	3A-	D).	All	
VP2/0-	positive	cells	were	iLOV-	positive.	Analysis	of	the	P1	and	P5	
RV1A-	iLOV	stocks	by	RT-	PCR	revealed	that	exogenous	 iLOV	DNA	
was	 stably	 retained	within	 the	RV	genome	over	 five	passages	 (P1	
to	P5)	 (Figure	3E).	Sequence	analysis	of	 the	 iLOV	 insert	confirmed	
these	results	and	revealed	no	mutations	(data	not	shown).
3.4 | Assessment of antiviral effects using RV1A- 
iLOV in vitro
We	 explored	 the	 application	 of	 RV1A-	ilOV	 to	 antiviral	 drug	
screening.	 Bafilomycin	 has	 previously	 been	 shown	 to	 inhibit	 RV	
F IGURE  1 GFP	ORF	insertion	into	the	rhinovirus	genome	is	deleted.	A,	Schematic	presentation	of	the	insertion	of	GFP	into	RV	genome.	
RV	proteins	are	presented	in	boxes.	2Apro	cleavages	at	points	indicated	by	yellow	solid	triangles	separate	RV	structural	from	nonstructural	
proteins	and	releases	GFP	proteins.	Solid	blue	arrows	indicate	3Cpro	cleavage	sites.	B,	Plaque	morphology	of	HeLa	cells	infected	with	
parental	wild-	type	RV1A	or	RV1A-	GFP.	C,	Western	blot	analysis	of	whole-	cell	lysates	from	HeLa	cells	infected	with	RV1A	or	RV1A-	GFP.	
Samples	were	probed	for	the	presence	of	GFP	and	the	RV	structural	proteins	VP0	and	VP2.	GFP	input	was	made	from	whole-	cell	lysate	of	
pEGFP-	N1–transfected	HeLa	cells.	D,	Detection	of	RV1A-	GFP–infected	cells	by	live-	cell	imaging	and	immunofluorescence	staining.	HeLa	
cells	were	infected	at	an	MOI	of	0.1	with	either	sham,	parental-	RV1A	or	RV1A-	GFP	for	16	h.	HeLa	cells	were	transfected	with	pEGFP-	N1	
for	16	h	(bar,	50	μm).	RV	VP2/0	protein	was	detected	using	AF555-	conjugated	anti-	VP2/0	Ab	(red);	iLOV	(green)	was	directly	detected	by	
blue	laser;	nuclei	were	stained	by	DAPI	(shown	in	black;	bar,	50	μm).	E,	RT-	PCR	analysis	of	RV-	GFP	and	RV-	RL	genomes.	RV-	GFP	and	RV-	RL	
genomic	RNA	were	isolated	from	plaque-	purified	virus	stocks.	RV1A-	GFP	and	RV1A-	RL	infectious	cDNA	clones	were	used	as	a	template	for	
amplification	of	complete	GFP	or	RL	sequence
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infection.30	We	 infected	HeLa	 cells	 with	 RV1A-	iLOV	 at	 an	MOI	
of	0.1	for	24	hours	in	the	presence	of	different	concentrations	of	
bafilomycin.	iLOV	expression	was	examined	using	flow	cytometry	
(Figure	4A).	 Consistent	 with	 previous	 work,30	 bafilomycin	 com-
pletely	inhibited	iLOV	expression	at	a	concentration	of	0.1	μmol/L	
(Figure	4A,B)	 and	 significantly	 reduced	 the	 viral	 titers	 of	 both	
RV1A	and	RV1A-	iLOV	(Figure	4C).	These	results	demonstrate	the	
potential	utility	of	the	iLOV	construct	to	measure	RV	protein	ex-
pression	in	vitro.
3.5 | Induction of cytokines in RV1A- iLOV–
infected mice
We	previously	showed	RV1B,	a	minor	group	virus,	triggers	inflamma-
tion	and	cytokine	expression	in	mice.11	We	therefore	tested	whether	
the	iLOV	insert	influences	RV	replication	and	RV-	induced	inflamma-
tory	responses	in	vivo.	Eight-	week-	old	mice	were	infected	with	RV1A	
and	RV1A-	iLOV	for	up	to	4	days,	and	 lungs	were	harvested	at	dif-
ferent	time	points	after	infection	and	processed	for	positive-	strand	
viral	RNA.	Measurement	of	RV	copy	number	and	viral	titers	showed	
no	 statistical	difference	 in	viral	 load	between	RV1A-	iLOV	and	 the	
parental	RV1A	at	each	of	the	indicated	time	points	(Figure	5A).
Studies	 in	 coxsackievirus	 have	 shown	 that	 large	 insertions	 at	
the	analogous	capsid	protein	P-	1D	protease	2A	junction	may	delete	
readily.31,32	iLOV	stability	in	vivo	was	therefore	examined	by	RT-	PCR	
at	 each	 of	 the	 indicated	 time	 points	 (Figure	5B).	 The	 intact	 iLOV	
fragment	(~600-	bp	band)	along	with	a	size-	reduced	band	(~300	bp)	
appeared	 in	 RV1A-	iLOV–infected	 mice.	 Sequence	 analysis	 of	 the	
size-	reduced	band	revealed	the	deletion	of	the	coding	sequence	for	
intact	iLOV	plus	three	nucleotides	from	2Apro	(see	sequence	in	Table	
S1).	Retention	of	the	iLOV	insert	was	approximately	90%	at	the	indi-
cated	time	points	(Figure	5B,C).
We	next	examined	cytokine	mRNA	expression	in	RV1A-	iLOV–in-
fected	mice.	Lungs	were	harvested	one	day	after	infection.	Similar	to	
the	parental	RV1A	virus,	RV1A-	iLOV	increased	lung	mRNA	levels	of	
Il1b, Ifnb1, Ifng, Cxcl1, Cxcl10, Cxcl2, and Ccl2	 (Figure	5D).	However,	
Ifng and Cxcl10	mRNA	expressions	were	decreased	for	RV1A-	iLOV	
compared	to	RV1A,	perhaps	because	of	the	slightly	reduced	growth	
rate.	No	induction	of	Ccl5 or Il10	was	observed	for	either	RV1A	or	
RV1A-	ilOV.
3.6 | Detection of iLOV in lungs of infected mice
HeLa	cells	were	plated	on	coverslips,	infected	with	RV1A-	iLOV,	and	
fixed	 in	4%	paraformaldehyde.	A	fluorescent	signal	was	visualized,	
but	the	signal	was	rapidly	quenched,	likely	due	to	the	oxidation	and	
bleaching	of	 iLOV-	bound	 flavin	mononucleotide.	Similarly,	 imaging	
of	 fixed	 lung	 tissue	 from	 RV1A-	iLOV–infected	 mice	 failed	 to	 re-
veal	a	fluorescent	signal.	We	therefore	employed	an	anti-	iLOV	an-
tibody	for	 immunohistochemical	staining	and	 immunofluorescence	
F IGURE  2 Construction	of	the	infectious	recombinant	rhinovirus-	iLOV.	A,	Plaque	morphology	of	HeLa	cells	infected	with	parental	
wild-	type	RV1A	or	RV1A-	iLOV.	iLOV	(green)	expression	was	directly	detected	by	blue	laser	for	RV	plaques.	B,	Viral	copy	number	and	titers	
in	RV-	infected	HeLa	cells.	Cells	were	infected	with	RV1A	or	RV1A-	iLOV	at	an	MOI	of	0.1.	At	specified	times,	cells	were	harvested	for	
analysis.	Viral	copy	number	was	analyzed	by	quantitative	polymerase	chain	reaction.	Viral	titer	was	determined	by	TCID50	(n	=	3,	mean	±	
SD).	C,	Fluorescence	imaging	for	RV-	iLOV.	HeLa	cells	were	infected	with	parental	wild-	type	RV1A	or	RV1A-	iLOV	for	24	h	at	an	MOI	of	0.1.	
RV	VP2/0	protein	was	detected	using	AF555-	conjugated	anti-	VP2/0	Ab	(red);	iLOV	(green)	was	directly	detected	by	blue	laser;	nuclei	were	
stained	by	DAPI	(shown	in	black;	bar,	50	μm).	D,	Western	blot	assay	to	detect	the	expression	of	iLOV
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F IGURE  3 Stability	of	RV1A-	iLOV.	A,	Live-	cell	imaging	and	immunofluorescence	staining	of	RV1A-	iLOV–infected	HeLa	cells.	HeLa	cells	
were	infected	with	P1	and	P5	of	RV1A-	iLOV	for	24	h	at	an	MOI	of	0.1	RV	VP2/0	protein,	which	was	detected	using	AF555-	conjugated	anti-	
VP2/0	Ab	(red);	iLOV	(green)	was	directly	detected	by	blue	laser;	nuclei	were	stained	by	DAPI	(shown	in	black;	bar,	50	μm).	B,	The	number	of	
iLOV-	positive	cells	out	of	50	VP2/0-	positive	cells	was	counted.	All	VP2/0-	positive	cells	were	iLOV-	positive.	C	and	D,	iLOV	detection	in	HeLa	
cells	by	flow	cytometry.	Cells	were	transfected	with	pXJ41-	iLOV	or	infected	with	RV1A	or	RV1A-	iLOV,	harvested	24	h	later,	and	analyzed	as	
a	percentage	of	single	cells	(n	=	3,	mean	±	SEM).	E,	RT-	PCR	analysis	of	RV1A-	iLOV	genomes.	Parental	RV1A	or	RV1A-	iLOV	genomic	RNA	was	
isolated	from	HeLa	cells	infected	with	P1	or	P5	virus	stocks.	The	RV1A-	iLOV	infectious	cDNA	clone	was	used	as	a	template	for	amplification	
of	complete	iLOV	sequence
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imaging.	We	 infected	 mice	 with	 RV1A-	iLOV	 and	 harvested	 lungs	
one	day	postinfection.	We	have	previously	shown	that,	besides	air-
way	 epithelial	 cells,	 RV	 colocalizes	with	 CD68+	macrophages.13,14 
Immunohistochemical	staining	with	anti-	iLOV	showed	signal	in	both	
the	epithelium	and	macrophages	 (Figure	6A).	 Immunofluorescence	
similarly	 indicated	 localization	 in	 the	 airway	epithelium,	 as	well	 as	
colocalization	of	 iLOV	 (green)	with	VP2/0	 (red)	and	a	macrophage	
marker,	CD68	(blue,	Figure	6B).
We	 have	 previously	 shown	 that	 RV	 infection	 induces	 lung	
infiltration	 with	 CD11b-	positive,	 M2-	polarized	 exudative	 mac-
rophages.33	 For	 the	 analysis	 of	 intracellular	 iLOV,	 aliquots	 of	
lung	 mince	 were	 fixed,	 permeabilized,	 and	 incubated	 with	 the	
Cy3-	tagged	 anti-	iLOV	 prior	 to	 flow	 cytometry.	 Flow	 cytometric	
analysis	 showed	 similar	 increases	 in	 the	percentage	 for	CD45	+		
CD11b+	 cells	 in	 both	 RV1A-	 and	 RV1A-	iLOV–infected	 mice	
(Figure	6C),	 confirming	 the	 colocalization	 of	 lung	 macrophages	
and	RV.	However,	 a	 signal	was	detected	 in	CD45+	CD11b+	cells	
only	 in	 RV1A-	iLOV–infected	mice.	 Taken	 together,	 these	 results	
suggest	 RV1A-	iLOV	 as	 a	 potential	 tool	 to	 study	 RV-	induced	 re-
sponses	in	immature	mice.
4  | DISCUSSION
In	the	present	study,	we	sought	to	design	and	generate	a	recombi-
nant	RV1A	accommodating	fluorescent	marker	expression,	thereby	
allowing	 tracking	of	viral	 infection	 in	vivo.	Using	 reverse	genetics,	
we	engineered	and	constructed	recombinant	RV1A	infectious	cDNA	
clones	 harboring	 the	 coding	 sequences	 of	 GFP,	 RL,	 or	 iLOV.	 GFP	
and	RL	were	not	expressed	in	cultured	cells	due	to	deletion	during	
replication,	consistent	with	the	limited	packaging	capability	of	other	
picornaviruses.	On	the	other	hand,	the	smaller	fluorescent	protein	
construct,	iLOV,	was	stably	expressed	in	RV1A-	iLOV–infected	cells	
both	 in	 vitro	 and	 in	 vivo.	Evaluation	of	 iLOV	expression	was	used	
to	assess	the	antiviral	effects	of	bafilomycin	in	RV1A-	iLOV–infected	
cells	 in	 vitro.	 Further,	 in	 vivo	 studies	 showed	 that,	 compared	 to	
F IGURE  4 Assessment	of	antiviral	role	of	bafilomycin	using	RV1A-	iLOV.	HeLa	cells	were	infected	with	sham	or	RV1A-	iLOV	for	24	h.	
Selected	cells	were	treated	with	0.01	μmol/L,	0.1	μmol/L,	or	0.2	μmol/L	of	bafilomycin.	iLOV-	positive	cells	were	analyzed	as	a	percentage	of	
single	cells	(n	=	3,	mean	±	SEM).	Viral	titers	were	calculated	as	TCID50
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F IGURE  5 Viral	load	and	cytokine	expression	of	RV1A-	iLOV	in	vivo	infection.	Eight-	week-	old	BALB/c	mice	were	inoculated	with	sham,	
RV1A	or	RV1A-	iLOV.	A,	Whole	lung	was	harvested	at	the	indicated	time	points	and	used	for	measuring	viral	copy	number	and	titer.	B,	RT-	
PCR	analysis	of	RV1A-	iLOV	genomes.	Parental	RV1A	or	RV1A-	iLOV	genomic	RNA	was	isolated	from	infected	mice	at	indicated	time	points.	
The	RV1A-	iLOV	infectious	cDNA	clone	was	used	as	template	for	amplification	of	complete	iLOV	sequence.	C,	iLOV/RV	copy	ratio	in	RV1A-	
iLOV–infected	mice.	Total	lung	RNA	(1	μg)	from	RV1A-	iLOV–infected	mice	harvested	at	the	indicated	time	points	was	used	for	measuring	
iLOV	and	RV	genome	copy	numbers.	D,	Whole	lung	mRNA	expression	was	measured	one	day	postinfection	(N	=	4,	mean±SEM,	*different	
from	RV1A,	one-	way	ANOVA)
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parental	virus,	RV1A-	iLOV	yielded	a	similar	viral	load	and	level	of	cy-
tokine	mRNA	expression	in	the	lungs	of	infected	mice.	These	results	
suggest	RV1A-	iLOV	may	be	a	useful	molecular	tool	for	studying	the	
life	cycle	and	pathogenesis	of	RV.
Construction	 of	 recombinant	 viruses	 expressing	 fluorescent	
markers,	 especially	GFP,	 has	 been	 applied	 through	 reverse	 genet-
ics	 to	 RNA	 viruses	 including	 influenza	 virus,34	 Zika	 virus,35	West	
Nile	virus,36	respiratory	syncytial	virus,37	murine	coronavirus,38 and 
porcine	 reproductive	 and	 respiratory	 syndrome	 virus.39	 However,	
insertion	of	large	fluorescent	protein	coding	sequences	into	the	ge-
nome	of	the	picornaviruses,	a	group	of	small	RNA	viruses	whose	ge-
nome	sizes	range	from	7.2	to	8.5	kb,	has	been	problematic.	Insertion	
of	the	GFP	ORF	into	poliovirus	severely	impaired	viral	replication	and	
was	deleted	in	the	course	of	cell	culture	serial	passage.40	In	addition,	
an	attempt	to	construct	a	recombinant	foot-	and-	mouth	disease	virus	
(FMDV)	expressing	GFP	or	Renilla	luciferase	protein	failed,	likely	due	
to	the	limited	packaging	capability.41	Subsequent	construction	of	vi-
ruses	containing	 increasingly	 larger	 inserts	 suggested	300–400	nt	
F IGURE  6 Presence	of	iLOV	signal	in	the	airway	epithelium	and	lung	macrophages	of	RV1A-	iLOV–infected	mice.	A,Twenty-	four	hours	
after	infection,	lungs	were	fixed	in	formaldehyde	overnight,	embedded	in	paraffin,	sectioned	at	5	μm,	and	incubated	with	a	1:1000	dilution	
of	anti-	iLOV	or	isotype	control	IgG	(bar,	50	μm).	B,	Lung	sections	were	costained	with	AF-	488–conjugated	anti-	iLOV	(green),	AF-	555–
conjugated	anti-	VP2/0	(red),	and	Cy5-	conjugated	CD68	(far	red	optical	spectrum,	shown	in	blue).	C,	Lung	CD45	+	,	CD11b+,	iLOV+	cells	from	
RV-	infected	BALB/c	mice	were	identified	one	day	postinfection	and	analyzed	as	a	percentage	of	CD45	+		cells	(n	=	4	from	one	experiment).	
Data	are	presented	as	mean	±	SEM	(*different	from	sham,	P	<	0.05;	one-	way	ANOVA)
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as	the	maximum	size	to	be	inserted	into	FMDV	genome.	Consistent	
with	this,	RV1A	has	been	used	to	express	a	393-	nt–long	fragment	of	
HIV	gag	gene.24	Shorter	antigenic	tags	have	also	been	inserted	into	
the	nonstructural	proteins	of	poliovirus.42
Compared	to	GFP,	fluorescent	proteins	based	on	flavin-	binding	
LOV	 (light,	 oxygen,	 or	 voltage	 sensing)	 domain	 offer	 advantages	
owing	to	their	smaller	size	(354	nt),	pH,	and	thermal	stability.43	iLOV	
was	created	from	the	LOV2	domain	of	the	phototropin	2	plant	blue	
light	 receptor	 of	Arabidopsis thaliana.26	 Unlike	GFP-	based	 fluores-
cent	proteins	which	are	 inherently	 fluorescent,	 LOV	domains	 spe-
cifically	function	as	photosensory	modules	and	typically	bind	flavin	
mononucleotide	as	an	ultraviolet	blue	light-	absorbing	chromophore.	
Accordingly,	iLOV	has	been	used	as	a	reporter	gene	in	recombinant	
FMDV41	 and	 reovirus.44	 However,	 in	 the	 latter	 studies,	 iLOV	 ex-
pression	was	only	examined	in	cultured	mammalian	cells,	not	in	vivo	
experiments.	We	now	show	that	iLOV	is	expressed	in	RV1A-	iLOV–
infected	cells	 in	vivo.	Though	some	deletion	occurs	during	 in	vivo	
infection,	over	90%	of	the	recombinant	RV1A-	iLOV	retains	the	iLOV	
sequence.	However,	while	 iLOV	was	readily	detectable	 in	cultured	
HeLa	cells,	the	iLOV	fluorescence	was	rapidly	lost	in	fixed	cells	and	
lung	tissue,	likely	due	to	the	oxidation	and	bleaching	of	iLOV-	bound	
flavin	mononucleotide.	We	therefore	required	the	use	of	anti-	iLOV	
antibody	to	detect	RV1A-	iLOV.
Similar	 to	 viral	 proteins,	 iLOV	 protein	 is	 released	 from	 the	 RV	
polyprotein	 through	viral	 proteinase-	mediated	 auto-	cleavage	during	
viral	protein	production,	an	early	step	of	viral	replication.	Detection	
of	iLOV	in	mouse	tissue	is	therefore	highly	suggestive	of	viral	replica-
tion,	particularly	in	the	airway	epithelium.	However,	it	remains	unclear	
whether	iLOV	signal	in	macrophages	represents	replication	or	engulf-
ment	of	the	virus	by	phagocytosis.	Viral	replication	in	cultured	mac-
rophages	is	limited,45	though	it	has	recently	been	shown	that	airway	
epithelial	cells	promote	rhinovirus	replication	in	monocytic	cells.46
Because	 there	 are	more	 than	100	different	RV	 serotypes	 (in	
species	A	and	B	alone),	it	is	infeasible	to	develop	a	cross-	reactive	
antibody	for	RV.	Until	now,	only	one	antibody	has	been	available	
for	 this	 purpose,	 the	monoclonal	 antibody	 R16-	7.	 This	 antibody	
binds	to	the	VP2	capsid	protein	of	the	closely	related	RV-	A16	and	
RV-	A1	 strains6	 but	 not	 to	 RV-	A2,	 RV-	B14,	 or	 RV-	A49.15	We	 de-
veloped	a	recombinant	virus	with	a	fluorescent	marker	that	could	
be	 used	 for	 tracking	 of	 RV	 infection	 in	 vivo.	 We	 designed	 the	
iLOV	sequence	 to	be	 flanked	with	2Apro	 cleavage	sites	and	 then	
inserted	 between	 the	RV	 genomic	 sequences	 encoding	 the	VP1	
and	2A	proteins.	2Apro	mediates	auto-	cleavage	between	VP1	and	
2A	proteins.20,47	Since	self-	catalytic	cleavage	is	a	characteristic	of	
picornavirus	replication,	this	design	should	allow	extension	of	our	
technique	 to	 all	 human	RVs.	Given	 the	 fact	 that	 iLOV	 sequence	
was	 stably	maintained	within	 RV1A	 genome	 during	 consecutive	
passages,	 it	 is	 plausible	 that	 other	 RVs	 serotypes	would	 accom-
modate	 and	 maintain	 the	 stability	 of	 iLOV	 sequence.	 Though	
the	 2Apro	 cleavage	 sites	 of	 numerous	 RV	 serotypes	 are	 hetero-
geneous,48	 designing	 the	 flanked	2Apro	 cleavage	 sequence	 to	be	
serotype-	specific	 would	 guarantee	 the	 release	 of	 iLOV.	 Besides	
VP1-	2A	 cleavage	 site,	 the	 junction	 site	 between	 5′UTR	 and	 the	
N-	terminus	of	VP4	has	been	used	to	insert	GFP	in	the	genome	of	
coxsackie	A16	virus49;	however,	 the	 insertion	 impaired	viral	 rep-
lication.	Taken	together,	these	data	suggest	that	the	construction	
strategy	 for	RV1A-	iLOV	could	be	 applied	 to	other	RV	 serotypes	
for	 studying	 the	 life	 cycle	 of	 RV	 in	 cultured	 cells,	 screening	 for	
antiviral	drugs	and	for	the	pathogenesis	of	RV.
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